Dell Medical School

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

Retrieved on: 
Monday, April 15, 2024
FDA, Society, Niemann–Pick disease, EAP, American Academy, Patient, Assistant professor, NDA, MD, Deficit spending, Dell Medical School, Disease, PDUFA, University, NPC, SIMD, Pediatrics, Diagnosis, Assistant, Annual general meeting, Therapy, Neuroscience, Pharmaceutical industry

CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that new long-term real-world data from the arimoclomol expanded access program (EAP: NCT04316637) for the treatment of Niemann-Pick disease type C (NPC) was featured in an oral presentation during the Society for Inherited Metabolic Disorders (SIMD) 45th Annual Meeting taking place at the Sheraton/Le Meridien Charlotte Hotel Complex in Charlotte, NC, from April 14-17, 2024.

Key Points: 
  • “NPC presents a therapeutic challenge, lacking approved treatment options in the U.S. and invariably leading to progressive loss of independence due to physical and cognitive impairments.
  • Among these 26 adults, mean (standard deviation, SD) age at NPC diagnosis and arimoclomol initiation was 23.7 (9.0) and 28.5 (6.5) years, respectively.
  • Patients continued arimoclomol treatment for a mean of 21 months (range: 12-32) and 69% (18/26) had recorded miglustat use.
  • Dr. Patterson’s talk was entitled “Evaluation of the Long-Term Effect of Arimoclomol in NPC - 48 Months Data from CT-ORZY-NPC-002.”

Kaiser Permanente Bernard J. Tyson School of Medicine appoints Dr. John L. Dalrymple as new Dean and CEO

Retrieved on: 
Tuesday, April 16, 2024
Education, Harvard University, University, Reproductive biology, Moses Austin, Medical school, Hospital, Teaching, School, Health, Doctor of Philosophy, Brigham, Dell Medical School, MD Anderson Cancer Center, History, Medical education, OBGYN, Curriculum, Cone Health Women's Hospital, Dalrymple, Medicine, Ellen, Faculty, Harvard Medical School, Student, Massachusetts General Hospital, Nursing

PASADENA, Calif., April 16, 2024 /PRNewswire/ -- Today, the Board of Directors of the Kaiser Permanente Bernard J. Tyson School of Medicine (KPSOM) announced the appointment of physician, educator, and women's health expert John L. Dalrymple, MD, as the school's new Dean and CEO after an extensive national search. Dr. Dalrymple brings a wealth of academic leadership and teaching experience, respected expertise as a practicing physician, a proven record of delivering quality medical education and a commitment to advancing equitable healthcare. Dr. Dalrymple will begin his service as Dean and CEO on July 1, 2024.

Key Points: 
  • Dr. Dalrymple will begin his service as Dean and CEO on July 1, 2024.
  • Dr. Dalrymple currently serves as the senior associate dean for Medical Education at Harvard Medical School.
  • Together, we will ensure that our school remains at the forefront of innovation, equity, compassionate care, and excellence in medical education."
  • "I am deeply honored and immensely humbled to become part of this innovative, vibrant, and forward-thinking school and world-class healthcare organization.

The Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation

Retrieved on: 
Saturday, March 23, 2024
Science, Neurology, Software, Research, Health, Data Management, Health Technology, Technology, MSIN, Acceleration, Learning, Multiple sclerosis, 1-Click, Dell Medical School, Sclerosis, MSAA, Doctor of Philosophy, MD, University, Implementation Science, Novartis, Population health, Multimedia, Medical director, Nursing

SEQSTER PDM Inc. (“ SEQSTER ”), the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.

Key Points: 
  • SEQSTER PDM Inc. (“ SEQSTER ”), the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.
  • SEQSTER unifies people living with multiple sclerosis (MS), researchers, and care centers nationwide.
  • View the full release here: https://www.businesswire.com/news/home/20240321509514/en/
    Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation (Graphic: Business Wire)
    This announcement follows the creation of the Multiple Sclerosis Implementation Network™ (MSIN™), which MSAA launched in collaboration with Novartis Pharmaceuticals Corporation in May 2023.
  • "I am deeply honored and profoundly excited to witness the remarkable collaboration between MSAA, clinicians, academic researchers, industry partners, and SEQSTER for the Multiple Sclerosis Implementation Network.

Acadia Healthcare Enters Into a Joint Venture Partnership With Ascension Seton to Expand Behavioral Health Services in Austin, Texas

Retrieved on: 
Tuesday, January 9, 2024
Mental Health, Health, Infectious Diseases, Hospitals, Physical Therapy, Other Health, Managed Care, Student, Patient, Acadia Healthcare, Partnership, Dell Medical School, University, Organization, Hospital

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture partnership with Ascension Seton, one of the leading, integrated healthcare systems in Austin, Texas, and a part of the Ascension national health network.

Key Points: 
  • Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture partnership with Ascension Seton, one of the leading, integrated healthcare systems in Austin, Texas, and a part of the Ascension national health network.
  • This is Acadia’s second joint venture partnership with Ascension, having developed and opened Ascension Saint Thomas Behavioral Health Hospital in Nashville, Tennessee, in 2020.
  • “Through this joint venture, our organizations will partner in the delivery of high-quality behavioral healthcare to promote health and healing in the Austin community.
  • This joint venture will build upon our expertise while increasing the number of behavioral health beds and other behavioral health services available to patients throughout the region.”

Acadia Healthcare and Ascension Seton Form Joint Venture to Expand Behavioral Health Services in Austin

Retrieved on: 
Tuesday, January 9, 2024
Mental Health, Health, Infectious Diseases, Hospitals, Physical Therapy, Managed Care, Student, Patient, Acadia Healthcare, Dell Medical School, Mental health, Seton, Dell, Organization, Hospital

Ascension Seton and Acadia Healthcare announced today that the two organizations have formed a joint venture to expand access to behavioral healthcare in Austin, Texas, and surrounding communities.

Key Points: 
  • Ascension Seton and Acadia Healthcare announced today that the two organizations have formed a joint venture to expand access to behavioral healthcare in Austin, Texas, and surrounding communities.
  • Acadia has committed to employ Ascension Seton Shoal Creek’s inpatient behavioral health associates at the newly constructed expansion, set to open in late 2024.
  • This joint venture will build upon our expertise while increasing the number of behavioral health beds and other behavioral health services available to patients throughout the region.”
    Ascension Seton selected Acadia as their joint venture partner because of Acadia’s shared commitment to high-quality, compassionate, mission-driven care to improve the health of the individuals and communities they serve.
  • “Ascension shares our commitment to expanding access to high-quality behavioral health services and reforming the way mental health patients are seen and cared for,” said Chris Hunter, chief executive officer of Acadia Healthcare.

Newly Published Study Demonstrates Safety and Efficacy of Calyxo’s CVAC Aspiration System for Patients with Large Kidney Stones

Retrieved on: 
Tuesday, November 14, 2023
General Health, Medical Devices, Health, Science, Research, Safety, Mayo Clinic Arizona, Risk, Dell Medical School, Patient, Journal, PCNL, Kidney, Anticoagulant, Moses Austin, SURE, Standard of care, MD, University, Pain, Mayo Clinic, SFR, CVAC, Pharmaceutical industry, Medical imaging, Austin, Texas

“This study confirms that SURE with CVAC is an excellent option for patients with large stone burdens, especially patients who are high-risk to undergo PCNL or patients who prefer a more minimally invasive alternative to PCNL,” said Dr. Stern.

Key Points: 
  • “This study confirms that SURE with CVAC is an excellent option for patients with large stone burdens, especially patients who are high-risk to undergo PCNL or patients who prefer a more minimally invasive alternative to PCNL,” said Dr. Stern.
  • This study builds on a previous safety and feasibility study published in the Journal of Endourology in 2022, which demonstrated that the CVAC Aspiration System could safely navigate throughout the kidney, remove significantly more kidney stone volume, and clear a higher proportion of it compared to traditional basket techniques.
  • This new large-stone study is especially encouraging because it indicates patients may also be spared secondary procedures often required in kidney stone care.
  • The CVAC Aspiration System is a novel technology that uses irrigation and aspiration to remove kidney stones after laser lithotripsy with the goal of a surgically stone-free outcome.

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

Retrieved on: 
Thursday, November 2, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Knowledge, Dell Medical School, University of Washington School of Medicine, SMMT, University of Colorado School of Medicine, Associate, Therapy, University, Lung cancer, Head, MD, University of Texas at Austin, Drug, University of Ottawa Heart Institute, Thyroid, Summit, Drug development, Senior, Quality of life, Lung, Disease, JAMA Otolaryngology–Head & Neck Surgery, Immunotherapy, Patient, Moses Austin, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.
  • We are very excited to welcome Laura to our team.”
    Dr. Chow remains in active clinical practice as a medical oncologist specialized in lung and head and neck cancers.
  • She joins Summit from Fate Therapeutics, where she was the Vice President of Clinical Development in Solid Tumors.
  • Chow’s experience being on the ground floor of cancer immunotherapy is unmatched,” added Dr. Allen S. Yang, Chief Medical Officer at Summit.

University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center

Retrieved on: 
Monday, August 14, 2023
UT System, Partnership, University, Moses Austin, Shoulder, Education, Dell Medical School, University of Texas at Austin, Cancer, Milliken, Research, Monroe Dunaway Anderson, MD Anderson Cancer Center, Student, Hospital, MD, Patient, Physician, Anderson, Diagnosis, Health, Connecticut Board of Regents for Higher Education, Nursing, Pharmaceutical industry, Tourism, Longhorn, Central Texas, Regent

The University of Texas at Austin Medical Center will start with two new hospital towers — The University of Texas MD Anderson Cancer Center and a UT Austin hospital.

Key Points: 
  • The University of Texas at Austin Medical Center will start with two new hospital towers — The University of Texas MD Anderson Cancer Center and a UT Austin hospital.
  • Eltife noted that the total investment for these cornerstone projects of the new medical center is still in the discussion by the regents and is estimated at $2.5 billion.
  • Once approved, the hospitals will be built on the current site of UT Austin’s Erwin Center.
  • UT Austin and UT MD Anderson already share strong collaborative relationships that include breakthrough research in cancer detection, diagnosis, and treatment.

UnitedHealthcare Donates $1 Million To Seven Nonprofit Organizations in Texas

Retrieved on: 
Tuesday, July 25, 2023
Other Philanthropy, General Health, DEI (Diversity, Equity and Inclusion), Family, Social Services, Other Health, Consumer, Environmental, Social and Governance (ESG), Mental Health, Children, Hospitals, Health Insurance, Fitness & Nutrition, Professional Services, Philanthropy, University, Health, Primary, Secondary, Fund Raising, Education, Foundation, Spring Branch, American Journal of Preventive Medicine, NFP, Moses Austin, Depression, Food, Housing, Dell Medical School, Health education, Diabetes, Curriculum, Health equity, ZIP, Texas Association, Preventive healthcare, Loneliness, American Medical Association, NYSE, UNH, School, National Association Medical Staff Services, Health Resources and Services Administration, Nurse-Family Partnership, Client, American Journal, Patient, Social isolation, Risk, Mental, Bwindi Community Hospital, Optum, Transport, Community, Rural area, Nursing, Pharmaceutical industry, UnitedHealth Group

UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, is awarding $1 million in Empowering Health grants to seven community-based organizations in Texas to expand access to care and address social determinants of health for uninsured individuals and underserved communities.

Key Points: 
  • UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, is awarding $1 million in Empowering Health grants to seven community-based organizations in Texas to expand access to care and address social determinants of health for uninsured individuals and underserved communities.
  • In total, UnitedHealthcare is donating more than $11.1 million in grants through its Empowering Health program across 12 states.
  • “UnitedHealthcare is honored to support the important work these local organizations are doing to provide greater access to services for underserved communities in Texas,” said Don Langer, CEO, UnitedHealthcare Community Plan of Texas.
  • Since launching its Empowering Health commitment in 2018, UnitedHealthcare has now invested more than $62 million in Empowering Health grants, reaching nearly 11 million people through partnerships with community-based organizations in 30 states and the District of Columbia.

Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder

Retrieved on: 
Tuesday, July 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, GAD, University, Dell Medical School, Benzodiazepine, PAM, University of Texas at Austin, Doctor of Philosophy, Acquisition, MD, Patient, Risk, Psychiatry, Behavioural sciences, PAMS, Rest, Safety, Pharmaceutical industry, Engrailed

Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD).

Key Points: 
  • Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD).
  • ENX-102 is an investigational, highly selective GABA-A α2,3,5 positive allosteric modulator (PAM) and antagonist at α1-containing GABA-A channels.
  • “Translational and phase 1 clinical data indicate central target engagement with a highly differentiated safety and tolerability profile for ENX-102 vs. non-selective GABA-A PAMs such as benzodiazepines.
  • These data support further evaluation of ENX-102 for efficacy in generalized anxiety disorder,” said Kimberly Vanover, PhD, chief scientific officer of Engrail.